Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas

Table 4 Performance of each serum tumor maker in predicting advanced intraductal papillary mucinous neoplasms

	Overall	Benign	Advanced	P value1
CA19-9 (n = 151)
Median, IQR (U/mL)	9.7 (3.75-46.3)	6.05 (3.1-15.2)	46.3 (9.0-166.4)	< 0.0001
≥ 37/< 37 U/mL	40/111	9/83	31/8	< 0.0001
CEA (n = 151)
Median, IQR (ng/mL)	2.7 (1.85-4.16)	2.46 (1.67-3.44)	3.1 (2.05-5.3)	0.002
≥ 5/< 5 ng/mL	24/127	9/83	15/44	0.01
CA125 (n = 109)
Median, IQR (U/mL)	11.9 (8.0-17.35)	11.65 (6.8-16.6)	12.1 (8.7-18.8)	0.051
≥ 35 /< 35 U/mL	5/104	1/63	4/41	0.182
CA724 (n = 96)
Median, IQR (U/mL)	1.64 (1.04-3.17)	1.44 (1.02-2.7)	2.5 (1.16-6.8)	0.022
≥ 9.8/< 9.8 U /mL	9/87	2/56	7/31	0.035
CA242 (n = 28)
Median, IQR (U/mL)	7.44 (4.1-12.7)	5.7 (3.6-8.23)	9.8 (6.9-20.7)	0.174
≥ 20/< 20 U/mL	5/23	1/12	4/11	0.416

¹P values were based on student’s t test comparing mean values of each serum tumor maker. CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; IQR: Interquartile range.